The global biosimilars market size was estimated at USD 33.92 million in 2024 and is projected to reach USD 151.58 million by 2033, growing at a CAGR of 18.27% from 2025 to 2033. This robust growth reflects the increasing acceptance of biosimilars as effective and affordable alternatives to reference biologic drugs. One of the primary drivers of this expansion is the cost-effectiveness of biosimilar therapies, which significantly reduce treatment expenses for patients and healthcare systems compared to branded biologics. Additionally, the rising prevalence of chronic disorders such as cancer, diabetes, autoimmune diseases, and inflammatory conditions worldwide is increasing the demand for long-term biologic treatments, thereby accelerating the adoption of biosimilars.

Biosimilar drugs are comparatively easier to develop than original biologics, as they rely on existing reference products for clinical benchmarking. This reduces the overall investment required for research and development while still delivering comparable therapeutic outcomes. The lower development and manufacturing costs associated with biosimilars can substantially reduce healthcare expenditures, making advanced therapies more accessible to a broader patient population. Furthermore, the combination of reduced production costs and rising market demand creates attractive profit opportunities for manufacturers, encouraging them to shift their focus toward biosimilar development. This transition is expected to further stimulate market growth. Although biosimilars may contain minor variations in molecular structure or formulation, they are rigorously evaluated and considered equivalent to their reference biologics in terms of safety, efficacy, and quality.

A comprehensive regulatory framework governs the approval and commercialization of biosimilar drugs to ensure patient safety and therapeutic consistency. Multiple regulations are in place to assess biosimilar compatibility with reference biologics, including analytical, preclinical, and clinical studies. For example, the U.S. Food and Drug Administration’s Abbreviated New Drug Application (ANDA) process requires applicants to scientifically demonstrate that their biosimilar performs in a manner similar to the original biologic. This includes proving comparable pharmacokinetics, such as demonstrating that the biosimilar reaches the bloodstream within a similar timeframe as the reference product. Such stringent regulatory oversight helps establish confidence among healthcare providers and patients, thereby supporting wider market adoption and increased market share for biosimilars.

Recent regulatory approvals are creating additional growth opportunities in the biosimilars market. In 2022, the U.S. FDA approved three cancer-related biosimilars, which were expected to enter the market in 2023. These approvals highlight the growing momentum of biosimilars in oncology and other therapeutic areas. The expanding opportunity landscape is also encouraging leading pharmaceutical companies to increase investments in biosimilar research and development. For instance, according to an article published in Business Today in April 2022, Biocon Biologics announced plans to increase its R&D expenditure by 10% to 15% to advance its biosimilar pipeline. This strategic move is expected to strengthen the company’s long-term market position. Overall, the pharmaceutical industry is witnessing a significant surge in biosimilar drug development, supported by favorable regulations, technological advancements, and rising global demand.

Key Market Trends & Insights:

• North America dominated the biosimilars market with the largest revenue share of 42.73% in 2024, primarily driven by the high adoption of cost-effective alternatives to branded biologics. The presence of a well-established healthcare infrastructure, favorable reimbursement policies, and strong regulatory support has facilitated faster uptake of biosimilars across the region. Within North America, the U.S. accounted for the largest market revenue share in 2024, supported by the rapid acceptance of monoclonal antibody and insulin biosimilars across hospitals and specialty care settings.
• The Asia Pacific region is expected to grow at the fastest CAGR of 19.67% over the forecast period. This growth is fueled by the increasing prevalence of diabetes, cancer, and autoimmune disorders, along with expanding patient populations and improving access to healthcare services. Additionally, growing awareness of biosimilars, rising healthcare expenditure, and strong manufacturing capabilities in countries such as India, China, and South Korea are contributing to accelerated regional growth.
• By drug class, the monoclonal antibodies (mAbs) segment led the market with the largest revenue share of 44.98% in 2024. This dominance is attributed to the increasing adoption of biosimilar monoclonal antibodies for the treatment of chronic and life-threatening conditions, including cancer and autoimmune diseases. Meanwhile, the insulin & analogues segment is projected to grow at the fastest CAGR of 20.37% over the forecast period, driven by the rapidly increasing global prevalence of diabetes and the growing need for affordable insulin therapies.
• By indication, the autoimmune disorders segment including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, and ankylosing spondylitis accounted for the largest revenue share of 39.98% in 2024. This growth is driven by the rising incidence of chronic inflammatory conditions and the long-term nature of treatment, which increases demand for cost-effective biologic alternatives. The oncology segment, covering breast, colorectal, lymphoma, lung, and gastric cancers, is projected to grow at the fastest CAGR of 19.36% over the forecast period, supported by the increasing global cancer burden and expanding approvals of oncology biosimilars.
• By end use, the hospitals segment led the market with the largest revenue share of 52.09% in 2024. This can be attributed to high patient inflow, availability of specialized healthcare professionals, and structured treatment protocols that support the administration of biosimilars. In contrast, the specialty pharmacies segment is projected to grow at the fastest CAGR of 17.94% over the forecast period. This growth is driven by the increasing demand for home-based treatment options, enhanced patient convenience, and the expanding role of specialty pharmacies in managing chronic disease therapies.

Order a free sample PDF of the Biosimilars Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 33.92 Million
• 2033 Projected Market Size: USD 151.58 Million
• CAGR (2025-2033): 18.27%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Players

• Amgen Inc.
• F Hoffman-La Roche Ltd.
• Sandoz International GmbH
• Reddy’s Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Samsung Biopis
• Biocon
• Viatris Inc.
• Celltrion Healthcare Co., Ltd.
• AbbVie Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the global biosimilars market is poised for strong growth, driven by rising demand for cost-effective biologic alternatives and the increasing prevalence of chronic diseases worldwide. Favorable regulatory frameworks and growing confidence in the safety and efficacy of biosimilars are supporting wider adoption across key therapeutic areas. Continuous investments in research and development by leading pharmaceutical companies are further strengthening product pipelines and market competitiveness. Regional expansion, particularly in Asia Pacific, along with growing uptake in oncology and autoimmune indications, is expected to sustain long-term market momentum. Overall, biosimilars are set to play a critical role in improving treatment accessibility while reducing healthcare costs globally.